Embed Size (px)
DESCRIPTION
“PharmaPoint: Type 2 Diabetes - Spain Drug Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. In the emerging markets in particular, uptake of branded drugs will increase due to rapid economic growth. Please email us at [email protected] or visit the http://www.reportstack.com/product/146567/pharmapoint-type-2-diabetes-spain-drug-forecast-and-market-analysis-to-2022.html to know more details
Citation preview
PharmaPoint: Type 2 Diabetes - Spain Drug Forecast and Market Analysis to 2022
Reportstack
Reportstack Contact - [email protected]
Reportstack Contact - [email protected]
Summary “PharmaPoint: Type 2 Diabetes - Spain Drug Forecast and Market Analysis to 2022”.
The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. In the emerging markets in particular, uptake of branded drugs will increase due to rapid economic growth. We anticipate that the type 2 diabetes market will not experience a fundamental shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the novel class of SGLT-2 inhibitors will occur; however, DPP-4 inhibitors and GLP-1 receptor agonists will continue dominating the noninsulin type 2 diabetes space.
A dip in sales caused by Actos patent expiry in 2012 and three insulin products’ patent expiry by 2015 will be offset by 16 pipeline product launches over the forecast period. Byetta’s patent expiration in 2016 will not have a major impact on the market as its sales have been constantly declining, with Victoza and Bydureon overtaking its shares.
Reportstack Contact - [email protected]
Scope of the report Overview of type 2 diabetes including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Spain from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting Spain type 2 diabetes market.
Key Benefits Understand and capitalize by identifying products that are most likely to ensure a
robust return
Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2012-2022 in Spain
Reportstack Contact - [email protected]
Reportstack Contact - [email protected]
If you are interested...
ContactDebora WhiteReportstack Market ResearchEmail: [email protected]: +1-888-789-6604
http://www.reportstack.com
